SEATTLE, WA--(Marketwired - Mar 7, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing the complex nature of the cannabis plant and the entourage effect of the plant's cannabinoids, terpenes, and other phytochemicals. GB Sciences Inc.'s (OTCQB: GBLX) holistic approach to cannabis drug development is a reflection and an embrace of this complexity.
THC-only pharmaceuticals, like Marinol (dronabinol) and Cesamet (nabilone), have experienced limited efficacy. In fact, less than 2% of patients in a 2011 survey preferred THC-only pharmaceuticals over inhaled or infused delivery methods. CBD-only therapies have proven much more beneficial -- particularly with conditions like epilepsy -- but emerging evidence has shown that combinations of these cannabinoids could be even more beneficial.
Dr. Than Russo, M.D., a neurologist who has become an expert in cannabinoids, notes many of these synergies in his study "Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects," which details many cannabinoid interactions.
There are also over 100 other cannabinoids in the cannabis plant that work together to reach therapeutic goals. For example, CBC is the third most common cannabinoid in the cannabis plant and works with THC to fight inflammation. THCv is another cannabinoid that has been shown to mitigate some of the negative psychoactive impacts of THC. These kinds of combinations could produce safer and more effective therapies targeting many conditions.
GB Sciences has embraced the complexity of both the cannabis plant and endocannabinoid system. By taking a holistic approach, the company aims to leverage the natural interactions between hundreds of cannabinoids, terpenes, and other phytochemicals within the cannabis plant on many different receptors within the endocannabinoid system. These targets are identified using a high-throughput screening system that incorporates cellular and animal models of disease, as well as in silico experiments run with sophisticated algorithms.
Recently, the company filed a series of patents covering cannabinoid-containing complex mixtures, addressing areas like neuronal protection (Parkinson's, Alzheimer's, Huntington's, etc.) and inflammation (arthritis, IBS, Crohn's, asthma, etc.). The company also licensed an existing patent from Makai Biotechnology covering therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies of the cardiovascular system.
With these patents in place, GB Sciences recently engaged a California-based contract research organization that will help complete pre-clinical trials on animals, file an Investigational New Drug application to begin human testing, and conduct its first human clinical trials. The company is taking a very clinical approach to the market to ensure the highest levels of standardization for both safety and efficacy reasons. Its manufacturing facility features standardized cultivation and extraction techniques designed to produce products with refined clinical properties, and it is applying for ISO certification for the facility. These levels of standardization are necessary for regulatory approvals as it moves into clinical trials.
Please follow the link to read the full article: http://www.cannabisfn.com/cannabinoids-work-best-together/
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.